ISPY-P1.01:Evaluating the Safety of Weekly Paclitaxel With Trastuzumab Duocarmazine (SYD985) in Patients With Metastatic Cancer
Status: WITHDRAWN
Study type: INTERVENTIONAL
Conditions: HER2-positive Breast Cancer|HER2 Low|SYD-985|SYD985|Vic-trastuzumab Duocarmazine|Metastatic Cancer|Metastatic Breast Cancer|Metastatic Gastrointestinal Carcinoid Tumor|Metastatic|HER2 Low Breast Cancer|GastroEsophageal Cancer|Gastroesophageal Adenocarcinoma|Endometrium Tumor|Ovarian Cancer|Ovarian Carcinoma|HER2-positive Gastric Cancer|HER2-positive Metastatic Breast Cancer|HER2 Mutation-Related Tumors|HER-2 Protein Overexpression|HER2 Low HR Positive|HR Positive|Hormone Receptor-positive Breast Cancer|Estrogen Receptor Positive Tumor|Progesterone Receptor-positive Breast Cancer|Triple Negative Breast Cancer|Hormone Receptor Negative Breast Carcinoma|Bladder Cancer
Interventions: DRUG: Vic-trastuzumab duocarmazine (SYD985) + paclitaxel
Sponsor: QuantumLeap Healthcare Collaborative
Collaborators: Byondis B.V.